Regulus Therapeutics Stock News

Regulus Therapeutics Inc. (NASDAQ:RGLS) price closed lower on Tuesday, March 01, dropping -0.04% below its previous close. >> 5 Best Growth Stocks for 2022 << >> 5 Best Growth Stocks for 2022 << A look at the daily price movement shows that the last close reads $0.23, with intraday deals fluctuated between $0.222 and $0.24. … Regulus Therapeutics Inc. (NASDAQ: RGLS): Down -83.21% In 2022, Outlook Remains Strong Read More »

During the last session, Regulus Therapeutics Inc. (NASDAQ:RGLS)s traded shares were 0.45 million, with the beta value of the company hitting 2.02. At the end of the trading day, the stocks price was $0.23, reflecting an intraday loss of -6.62% or -$0.02. The 52-week high for the RGLS share is $2.32, that puts it down Regulus Therapeutics Inc. (NASDAQ: RGLS) Stock Dropped -6.08% Over A Month Are There Any Chances Of Growth? Read More »

SAN DIEGO , Feb. 10, 2022 /PRNewswire/ -- Regulus Therapeutics Inc . (NASDAQ: RGLS ), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that Jay Hagan , President and Chief Executive Officer of Regulus, will present at the 11 th Annual SVB Leerink Global Healthcare Conference on Friday, February 18, 2022 at 3:00 p.m. ET . A live webcast of the presentation will be available under "Events and Presentations" through the … Full story available on Benzinga.com

The US economy grew 6.9% on quarter during the last three months of previous year, up from 2.3% expansion in the prior quarter and also above market estimates of 5.5%. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company''s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga''s insider transactions platform. OpGen The Trade: OpGen, Inc. (NASDAQ: OPGN ) Chief Operating Officer Johannes Bacher acquired a total of 25,000 shares at an average price of $0.85. To acquire these shares, it cost $21.25 thousand. Whats Happening: OpGen recently said it sees preliminary FY21 sales of $4.3 million. What OpGen Does: OpGen Inc is a precision Full story available on Benzinga.com

After losing some value lately, a hammer chart pattern has been formed for Regulus (RGLS), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisio

Regulus Therapeutics Inc. (NASDAQ:RGLS) has a beta value of 2.01 and has seen 1.38 million shares traded in the last trading session. The company, currently valued at $32.57M, closed the last trade at $0.36 per share which meant it gained $0.02 on the day or 5.83% during that session. The RGLS stock price is -544.44% An In-Depth Look At Regulus Therapeutics Inc. (RGLS) Read More »

Regulus Therapeutics Inc. (NASDAQ:RGLS) with the stream of -4.91% also noticed, India 1847 Goedeker Inc. (AMEX:GOED) encountered a rapid change of -3.35% in the last hour of Fridays trading session. The post Remarkable Stock in Review: Regulus Therapeutics Inc. (NASDAQ:RGLS), 1847 Goedeker Inc. (AMEX:GOED) appeared first on Stocks Equity .

Zacks Investment Research upgraded shares of Regulus Therapeutics (NASDAQ:RGLS) from a sell rating to a hold rating in a report published on Wednesday morning, Zacks.com reports. According to Zacks, Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs, called microRNA therapeutics. The Companys products aim to treat or [] The post Regulus Therapeutics (NASDAQ:RGLS) Upgraded by Zacks Investment Research to Hold appeared first on ETF Daily News .

Zacks Investment Research upgraded shares of Regulus Therapeutics (NASDAQ:RGLS) from a sell rating to a hold rating in a research note issued to investors on Wednesday morning, Zacks.com reports. According to Zacks, Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs, called microRNA therapeutics. The Companys products aim []

Regulus Therapeutics Inc. (NASDAQ:RGLS) with the stream of -3.25% also noticed, India B2Gold Corp. (AMEX:BTG) encountered a rapid change of -1.91% in the last hour of Tuesdays trading session. Regulus The post Traders should take notice on: Regulus Therapeutics Inc. (NASDAQ:RGLS), B2Gold Corp. (AMEX:BTG) appeared first on Stocks Equity .

State Street Corp bought a new stake in Regulus Therapeutics Inc. (NASDAQ:RGLS) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 176,494 shares of the biopharmaceutical companys stock, valued at approximately $144,000. State Street Corp owned approximately 0.20% of Regulus Therapeutics [] The post State Street Corp Buys New Shares in Regulus Therapeutics Inc. (NASDAQ:RGLS) appeared first on ETF Daily News .

In the last trading session, 1.36 million Regulus Therapeutics Inc. (NASDAQ:RGLS) shares changed hands as the companys beta touched 2.01. With the companys per share price at $0.34 changed hands at -$0.03 or -6.85% during last session, the market valuation stood at $31.80M. RGLSs last price was a discount, traded about -582.35% off its 52-week Why To Invest In Regulus Therapeutics Inc. (NASDAQ: RGLS) Stock? Read More »

SAN DIEGO , Dec. 1, 2021 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced a presentation at the first annual Rare & Genetic

Regulus Therapeutics (NASDAQ:RGLS) and OncoSec Medical (NASDAQ:ONCS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, analyst recommendations, earnings, dividends and profitability. Insider & Institutional Ownership 26.3% of Regulus Therapeutics shares are owned by institutional investors. Comparatively, []

Regulus Therapeutics Inc. (RGLS) with the stream of -4.87% also noticed, India PetVivo Holdings, Inc. Warrant (PETVW) encountered a rapid change of 4.35% in the last hour of Mondays trading The post Have a grip on this: Regulus Therapeutics Inc. (NASDAQ:RGLS), PetVivo Holdings, Inc. Warrant (NASDAQ:PETVW) appeared first on Stocks Equity .